Notices. Notice of application
394 words·~2 min read·
/register/2017/04/25/2017-08344A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-392] Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc. ACTION: Notice of application. DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017. ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance Drug code Schedule Cathinone 1235 I Methcathinone 1237 I Mephedrone (4-Methyl-N-methylcathinone) 1248 I Aminorex 1585 I Alpha-ethyltryptamine 7249 I Lysergic acid diethylamide 7315 I Tetrahydrocannabinols 7370 I 4-Bromo-2,5-dimethoxyamphetamine 7391 I 4-Bromo-2,5-dimethoxyphenethylamine 7392 I 4-Methyl-2,5-dimethoxyamphetamine 7395 I 2,5-Dimethoxyamphetamine 7396 I 3,4-Methylenedioxyamphetamine 7400 I N-Hydroxy-3,4-methylenedioxyamphetamine 7402 I 3,4-Methylenedioxy-N-ethylamphetamine 7404 I 3,4-Methylenedioxymethamphetamine 7405 I Dimethyltryptamine 7435 I Psilocybin 7437 I 5-Methoxy-N,N-diisopropyltryptamine 7439 I 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N-Benzylpiperazine 7493 I MDPV (3,4-Methylenedioxypyrovalerone) 7535 I Methylone (3,4-Methylenedioxy-N-methylcathinone) 7540 I Heroin 9200 I Normorphine 9313 I Norlevorphanol 9634 I Amphetamine 1100 II Methamphetamine 1105 II Nabilone 7379 II 1-Phenylcyclohexylamine 7460 II Phencyclidine 7471 II Cocaine 9041 II Codeine 9050 II Ecgonine 9180 II Levomethorphan 9210 II Levorphanol 9220 II Meperidine 9230 II Metazocine 9240 II Methadone 9250 II Morphine 9300 II Thebaine 9333 II Levo-alphacetylmethadol 9648 II Remifentanil 9739 II Sufentanil 9740 II Carfentanil 9743 II Fentanyl 9801 II The company plans to manufacture reference standards.
Dated: April 18, 2017. Louis J. Milione, Assistant Administrator. [FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]
Connectionstraces to 2
2 references not yet in our index
- 21 CFR 1301
- 28 CFR 0
Citation graph
cites case law
Cites 4Cited by 0 across 0 sources